CLINICAL_TRIALS
research
· 2016-09-09
Clinical Trial Update: Efficacy Study of CHG Regimen vs Decitabine to Treat Higher-risk MDS [Phase 2, Phase 3]
Summary
An update on a Phase 2/Phase 3 trial evaluating CHG regimen versus Decitabine for higher-risk myelodysplastic syndromes; no results are provided.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Xiao Li | Conditions: Myelodysplastic Syndromes | Phase 2, Phase 3 | Status: UNKNOWN